- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT03248518
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases (LIFT)
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases: A Randomised Clinical Trial
Fatigue is common and disabling for most patients with inflammatory rheumatic disease. Therapies designed to improve physical activity and 'talking' treatments, which positively help patients change the way they think and behave, are both helpful in reducing the burden of the fatigue. However, few patients have access to these treatments in most health services. This situation results from the absence of standardised programmes and limited availability of relevant therapists.
The investigators aim to enhance access to fatigue alleviating physical activity and talking therapies by testing innovative,standardised and cost-effective approaches to treatment delivery.
The investigators will also use this opportunity to understand how to select the best treatment for a patient based on their individual profile and to better understand how these treatments actually work. This in turn may lead to more refined and effective therapies in the future.
Обзор исследования
Статус
Условия
Подробное описание
Eligible participants will be identified from patients with inflammatory rheumatic diseases attending major secondary care rheumatology services in the United Kingdom. Potential participants will be identified using local databases/clinic lists and will then be mailed a pre-study invite, which will include questions about fatigue. Potentially eligible participants will be invited to attend a baseline assessment.
Once it has been confirmed at the baseline assessement that they are eligible to take part in the study, the consented participant will be allocated to one of three treatment groups. During the course of the trial, the participant will be invited to visit the study centre three more times for assessments.
At each of the four assessment visits (baseline, and approximately 2, 7 and 13 months after) they will be asked:
- To complete questionnaires which collect information about various outcomes which we think will improve in response to the therapies under evaluation as well as factors which will help us understand how the treatments may work, and factors which may help identify those patients better suited to one therapy over another
- To provide a blood sample for research
- To take part in an aerobic fitness test
- To wear an activity monitor for the next 7 days which will be fitted at each visit
- To answer three short questions about engagement with intervention delivered by telephone from trial office at the time of session 4 and 8 (CBA and PEP intervention only). Similarly, the allocated therapists will be asked to give their view of the participants' engagement with the intervention.
All participants will be asked to keep a diary on any other treatments they are using in addition to the treatments they may receive during the study and how costly these other treatments are. The diary period will last for the first 6 months and then for 2 weeks after the third visit and 2 weeks before the last visit.
After they finished the study, the investigators may approach a subgroup of participants who received either the talking therapy or the personalised exercise programme again and ask for an interview to enable more detailed feedback on if they found the intervention helpful and how it has changed their daily life.
Тип исследования
Регистрация (Действительный)
Фаза
- Непригодный
Контакты и местонахождение
Места учебы
-
-
-
Aberdeen, Соединенное Королевство
- NHS Grampian
-
Dundee, Соединенное Королевство
- NHS Tayside
-
Edinburgh, Соединенное Королевство
- NHS Lothian
-
Glasgow, Соединенное Королевство
- NHS Greater Glasgow and Clyde
-
Newcastle Upon Tyne, Соединенное Королевство, NE7 7DN
- Newcastle upon Tyne Hospitals NHS Foundation Trust
-
Stoke on Trent, Соединенное Королевство, ST6 7AG
- Midlands Partnership NHS Foundation Trust
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- be ≥ 18 years at the time of consent
- have been diagnosed with rheumatoid arthritis (RA), systemic lupus erythematous (SLE), axial spondyloarthritis (AxSpA) or psoriatic arthritis (PSA) by a rheumatologist
- report fatigue to be a persistent problem
- have access to a telephone landline or mobile telephone and/or internet based audio/video calls
- give permission for researchers to access their hospital medical notes
- currently be under the care of a secondary care physician
- have stable disease as evidenced by no change in immunomodulatory therapy within the last three months based on the hospital medical record
Exclusion Criteria:
- there are significant abnormalities of thyroid function (TSH levels) on the most recent blood test done within the last three months
- there is evidence of severe anaemia (haemoglobin levels) on the most recent blood test done within the last three months
- there is evidence of severe renal dysfunction (eGFR) on the most recent blood test done within the last three months
- they have a medical condition which would make the proposed interventions unsuitable, e.g. significant heart disease
- they are pregnant
- they are unable to understand English sufficiently to take part in the intervention
- they are unable to provide written informed consent
- they are not willing to be randomised
- they are currently participating in an interventional clinical trial
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Двойной
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
---|---|
Активный компаратор: Usual Care alone
Participants receive written information about fatigue which is designed as self-management guide.
|
Information booklet on fatigue which represents usual care in almost all UK rheumatology centres
|
Активный компаратор: CBA + usual care
In addition to usual care, participants receive a talking therapy using a cognitive behavioural approach.
The talking therapy will be delivered via telephone by a trained rheumatology health care professional who will contact the participant for 8 sessions over a period of 6 months.
|
Information booklet on fatigue which represents usual care in almost all UK rheumatology centres
A talking therapy which explicitly aims to replace unhelpful beliefs and behaviours through the application of patient-centred strategies and behavioural activities
Другие имена:
|
Активный компаратор: PEP + usual care
In addition to usual care, participants receive a personalised exercise programme.
After an initial face-to-face assessment, the remaining programme will be delivered via telephone by a trained rheumatology health care professional who will contact the participant for 7 sessions over a period of 6 months.
|
Information booklet on fatigue which represents usual care in almost all UK rheumatology centres
PEP is a graded exposure behaviour therapy which aims to gradually optimise patients levels of physical activity with view to modifying their altered perception of effort and ultimately reduce the severity and impact of fatigue.
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Fatigue (severity) using Chalder Fatigue Scale (Likert)
Временное ограничение: 56 weeks
|
Chalder Fatigue Scale (Likert), assessed at 56 weeks after baseline, between-group change CBA+UC vs UC and PEP+UC vs UC with main estimate of treatment effect at 56 weeks after randomisation, Main estimate of treatment effect at 56 weeks
|
56 weeks
|
Fatigue (severity) using Chalder Fatigue Scale (Likert)
Временное ограничение: 10 weeks
|
Chalder Fatigue Scale (Likert), assessed at 10 weeks after baseline, between-group change CBA+UC vs UC and PEP+UC vs UC
|
10 weeks
|
Fatigue (severity) using Chalder Fatigue Scale (Likert)
Временное ограничение: 28 weeks
|
Chalder Fatigue Scale (Likert), assessed at 28 weeks after baseline, between-group change CBA+UC vs UC and PEP+UC vs UC
|
28 weeks
|
Fatigue (impact) using Fatigue Severity Scale
Временное ограничение: 56 weeks
|
Fatigue Severity Scale, co-primary outcome assessed at 56 weeks after baseline, between-group change CBA+UC vs UC and PEP+UC vs UC with main estimate of treatment effect at 56 weeks
|
56 weeks
|
Fatigue (impact) using Fatigue Severity Scale
Временное ограничение: 10 weeks
|
Fatigue Severity Scale, co-primary outcome assessed at 10 weeks after baseline, between-group change CBA+UC vs UC and PEP+UC vs UC
|
10 weeks
|
Fatigue (impact) using Fatigue Severity Scale
Временное ограничение: 28 weeks
|
Fatigue Severity Scale, co-primary outcome assessed at 28 weeks after baseline, between-group change CBA+UC vs UC and PEP+UC vs UC
|
28 weeks
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Fatigue (physical, living, cognition and emotional aspects) using Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire
Временное ограничение: 0, 10 weeks, 28 weeks, 56 weeks after randomisation
|
Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire
|
0, 10 weeks, 28 weeks, 56 weeks after randomisation
|
Quality of life & health utility index
Временное ограничение: 0, 10 weeks, 28 weeks, 56 weeks after randomisation
|
SF-12
|
0, 10 weeks, 28 weeks, 56 weeks after randomisation
|
Pain using numerical rating scale
Временное ограничение: 0, 10 weeks, 28 weeks, 56 weeks after randomisation
|
Pain numerical rating scale
|
0, 10 weeks, 28 weeks, 56 weeks after randomisation
|
Anxiety and depression using Hospital anxiety and depression scale
Временное ограничение: 0, 10 weeks, 28 weeks, 56 weeks after randomisation
|
Hospital anxiety and depression scale
|
0, 10 weeks, 28 weeks, 56 weeks after randomisation
|
Impact on work using Work Productivity and Activity Impairment Questionnaire
Временное ограничение: 0, 10 weeks, 28 weeks, 56 weeks after randomisation
|
Work Productivity and Activity Impairment Questionnaire: Specific Health Problem
|
0, 10 weeks, 28 weeks, 56 weeks after randomisation
|
Impact on activities using Valued Life Activities Scale
Временное ограничение: 0, 10 weeks, 28 weeks, 56 weeks after randomisation
|
Valued Life Activities Scale
|
0, 10 weeks, 28 weeks, 56 weeks after randomisation
|
Change of global health
Временное ограничение: 10 weeks, 28 weeks, 56 weeks after randomisation
|
Single question to indicate perceived change in global health compared with last assessment visit
|
10 weeks, 28 weeks, 56 weeks after randomisation
|
Соавторы и исследователи
Спонсор
Соавторы
Следователи
- Главный следователь: Gary Macfarlane, PhD, University of Aberdeen
- Главный следователь: Neil Basu, MBChB, PhD, University of Glasgow
Публикации и полезные ссылки
Общие публикации
- Bachmair EM, Martin K, Aucott L, Dhaun N, Dures E, Emsley R, Gray SR, Kidd E, Kumar V, Lovell K, MacLennan G, McNamee P, Norrie J, Paul L, Packham J, Ralston SH, Siebert S, Wearden A, Macfarlane G, Basu N; LIFT study group. Remotely delivered cognitive behavioural and personalised exercise interventions for fatigue severity and impact in inflammatory rheumatic diseases (LIFT): a multicentre, randomised, controlled, open-label, parallel-group trial. Lancet Rheumatol. 2022 Jun 27;4(8):e534-e545. doi: 10.1016/S2665-9913(22)00156-4. eCollection 2022 Aug.
- Martin KR, Bachmair EM, Aucott L, Dures E, Emsley R, Gray SR, Hewlett S, Kumar V, Lovell K, Macfarlane GJ, MacLennan G, McNamee P, Norrie J, Paul L, Ralston S, Siebert S, Wearden A, White PD, Basu N. Protocol for a multicentre randomised controlled parallel-group trial to compare the effectiveness of remotely delivered cognitive-behavioural and graded exercise interventions with usual care alone to lessen the impact of fatigue in inflammatory rheumatic diseases (LIFT). BMJ Open. 2019 Jan 30;9(1):e026793. doi: 10.1136/bmjopen-2018-026793.
Полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Кожные заболевания
- Инфекции
- Заболевания иммунной системы
- Аутоиммунные заболевания
- Глазные болезни
- Заболевания суставов
- Заболевания опорно-двигательного аппарата
- Заболевания соединительной ткани
- Стоматогнатические заболевания
- Заболевания полости рта
- Кожные заболевания, папулосквамозный
- Заболевания позвоночника
- Заболевания костей
- Заболевания слезного аппарата
- Спондилоартропатии
- Псориаз
- Ксеростомия
- Заболевания слюнных желез
- Синдром сухого глаза
- Болезни костей, инфекционные
- Усталость
- Артрит
- Артрит, Ревматоидный
- Красная волчанка, системная
- Артрит, Псориатический
- Ревматические заболевания
- Коллагеновые заболевания
- Синдром Шегрена
- Спондилит
- Спондилоартрит
Другие идентификационные номера исследования
- 2.049.16
- Epi029 (Другой идентификатор: Epidemiology Group, University of Aberdeen)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .
Клинические исследования Usual Care
-
The University of Texas Health Science Center,...Еще не набираютПитание при беременности высокого рискаСоединенные Штаты
-
University of MichiganAgency for Healthcare Research and Quality (AHRQ)Завершенный
-
Chung Shan Medical UniversityЗавершенныйОпекун | Пациент с инсультомТайвань
-
Johnson & Johnson Vision Care, Inc.ЗавершенныйОстрота зрения, биомикроскопия с щелевой лампой (оценка окрашивания роговицы)Соединенные Штаты
-
New York UniversityIndiana University; Moi UniversityЗавершенный
-
University of AlbertaUniversity Hospital FoundationЗавершенныйМерцательная аритмияКанада
-
Brigham and Women's HospitalAgency for Healthcare Research and Quality (AHRQ)Еще не набираютСердечная недостаточность | Сахарный диабет | Диабет | Хронические заболевания почек | Хроническая сердечная недостаточность
-
Institute of Mental Health, SingaporeNational Healthcare Group, SingaporeРекрутингСлабоумие | Бремя воспитателя | Цифровое здоровьеСингапур
-
University Health Network, TorontoРекрутингЛимфома | Лимфопролиферативные заболевания | Рак молочной железы Стадия I | Рак молочной железы Стадия II | Колоректальный рак II стадии | Колоректальный рак III стадии | Рак молочной железы Стадия III | Колоректальный рак I стадии | Рак головы и шеи III стадия | Рак молочной железы, стадия 0 | Рак головы... и другие заболеванияКанада
-
Emory UniversityFoundation for Physical Therapy, Inc.ЗавершенныйИнсультСоединенные Штаты